Jefferies issues a GBp 2,500.00 target for GSK stock

Published on 10/26/2026 at 16:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GSK expects third-quarter results on October 28, 2026. GSK stock costs EUR 22.91 on October 26, 2026, up 1.33 percent versus the Xetra close.

Analyst target and reporting date

On October 20, 2026, Jefferies issued a GBp 2,500.00 target for GSK.
GSK is scheduled to report third-quarter results on October 28, 2026.
GSK stock costs EUR 22.91 at Lang & Schwarz on October 26, 2026 at 4:43 p.m. CEST, 1.33 percent above the Xetra close of October 23, 2026.
The London price stood at GBp 1,919.00 with a 16.09 price-to-earnings ratio.

GSK, GB00BN7SWP63, Illustration mit AI erstellt.

GSK (ISIN GB00BN7SWP63) received a GBp 2,500.00 price target from Jefferies on October 20, 2026, according to The Cerbat Gem. That target stands 30.28 percent above the London price of GBp 1,919.00 on October 26, 2026 at 4:52 p.m. London time. GSK stock was trading at EUR 22.91 at Lang & Schwarz on October 26, 2026 at 4:43 p.m. CEST, up EUR 0.30 or 1.33 percent versus the Xetra close of October 23, 2026 at EUR 22.61.

Target spread reaches 30.28 percent

Jefferies paired its target with a Buy rating in the October 20 research report. The same source listed Deutsche Bank at a GBp 2,000.00 target and Berenberg at GBp 2,200.00, while JPMorgan kept an Underweight rating and a GBp 1,700.00 target in a report dated October 20, 2026, as reported by FinanzNachrichten. The range of targets places the latest analyst views between GBp 1,700.00 and GBp 2,500.00.

GSK stock stays below its yearly high

The London quotation was 15.91 percent below its GBp 2,282.00 52-week high and 18.13 percent above its GBp 1,624.50 low on October 26, 2026. GSK carried a market capitalization of GBP 76.9 billion, a price-to-earnings ratio of 16.09 and a dividend yield of 4.00 percent. Trading volume stood at 1,354,903 shares at 4:52 p.m. London time.

October 28 brings the next test

GSK is scheduled to publish third-quarter results on October 28, 2026. Yahoo Finance reported that consensus calls for third-quarter revenue of USD 8.81 billion, up 3.00 percent from USD 8.55 billion a year earlier, while consensus earnings per share of USD 1.33 are 9.10 percent below USD 1.46.

Valuation meets a broad product base

GSK operates in healthcare and develops vaccines, specialty medicines and general medicines. Its portfolio spans HIV, oncology, respiratory and immunology treatments, while its vaccine business includes shingles, meningitis and respiratory syncytial virus products. The valuation figures place the analyst debate against a measurable stock position rather than a bare price move.

Stock position after the latest quote

The euro quotation remained above the October 23, 2026 Xetra close by 1.33 percent at the latest Lang & Schwarz timestamp. The further course of trading is shown by the continuously updated real-time quote of GSK stock.